IDH1/IDH2 Mutation Analysis by Next Generation Sequencing

Test Code

M IDH1/2

Associations

IDH mutations are recurrent in a variety of cancer settings including glial neoplasms, acute myeloid leukemias, cholangiocarcinomas, and chondrosarcomas, among others.

Methodology

Next Generation Sequencing Targeted HotSpots
QIAGEN® Human Tumor Actionable Mutations Panel (GeneRead™ DNAseq Targeted Panels V2) for targeted enrichment

Turnaround Time

10 days

Specimen Requirements

Formalin Fixed Paraffin Embedded tissue block
3 slides (3-5 uM) per marker on adhesion glass
NOTE: Include a surgical pathology report with the sample if sending a block and/or slides
5.0 mL (min. 3.0 mL) whole blood EDTA, Sodium Heparin or ACD
3.0 mL (min. 1.0 mL) bone marrow EDTA, Sodium Heparin or ACD

Specimen Stability

Indefinite at ambient temperature (18-25°C) Whole blood and Bone Marrow stable at 18-25°C for 72 hours or 4°C for up to 7 days

Storage & Handling

Ship ambient. Protect from extreme temperature with an ice pack. Separate ice pack from specimen

Causes for Rejection

Improper specimen labeling; Insufficient sample volume; Clotted specimen; Specimen older than 7 days

Description

Targeted next generation sequencing is performed to asses for the following pathogenic hotspot mutations: IDH1 p.R132 and IDH2 p.R140 and IDH2p.R172.

Trademarks

Qiagen and GeneRead are trademarks of Qiagen